Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

January 15, 2025

Special Announcement

IDHNow for AML Sponsored Testing Program

Your acute myeloid leukemia acute myeloid leukemia (AML) patients may be eligible for the IDHNow for AML Sponsored Testing Program. This exclusive program provides the IDH1/IDH2 Mutation Analysis by PCR test to patients who meet the eligibility criteria:

• Patient has newly diagnosed AML, and not previously treated
• Patient lives and receives treatment in the U.S. or a U.S. territory
• The patient does not have a known IDH1 mutation from a previous test
• The patient has not previously been tested under this program

To learn more and order today, visit the webpage.